Clinical Trial Update: A Study to Investigate the Safety and Efficacy of Replenine®-VF in Haemophilia B Patients Under the Age of 6 Years [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating the safety and efficacy of Replenine®-VF in haemophilia B patients under 6 years has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Haemophilia

Drugs mentioned

• Replenine®-VF (Factor IX concentrate)

Snippet

Sponsor: Bio Products Laboratory | Conditions: Haemophilia B | Phase 3 | Status: COMPLETED